SANOFI INDIA
|
|
BOM : 500674     NSE : SANOFI     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Apr 16,2024 |
Price(EOD): ₹ 8,395.80
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 19,310.34 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SANOFI INDIA | 0.4% | -15.6% | 33.1% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
FUNDAMENTAL ANALYSIS OF SANOFI INDIA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SANOFI INDIA
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
32.06
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 603.20 Cr
[Latest Qtr - Dec2023 - Standalone Results ] 19.04
P/B Calculated based on Book Value of Rs 1,015.50 Cr
[Latest Year - Dec2023 - Standalone Results ] 6.78
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2023 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
30% 36% 40% |
SHARE PRICE MOMENTUM OF SANOFI INDIA
SANOFI INDIA vs SENSEX
DEBT OF SANOFI INDIA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
- 0 0 - |
- - - - |
[Last Annual Data : Dec2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SANOFI INDIA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SANOFI INDIA
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-2.9% -10.12% -10.14% -9.53% |
3.27% 12.28% -0.84% 5.19% |
QtrlyTrend |
-2 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
SANOFI INDIA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 250 SMALLCAP | -0.8% | 6.7% | 62.2% |
S&P BSE SMALLCAP SELECT INDEX | -0.9% | 4.5% | 44.9% |
S&P BSE SMALL CAP | -1.3% | 6.1% | 62.6% |
S&P BSE 400 MIDSMALLCAP | -1.3% | 4.1% | 58.5% |
S&P BSE MIDSMALLCAP | -1.4% | 4.4% | 63.3% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY SMALLCAP250 | -0.7% | 6.9% | 68% |
NIFTY MID SMALL400 | -1.1% | 4.5% | 61.2% |
NIFTY500 MULTICAP 50:25:25 | -1.6% | 2.6% | 46% |
NIFTY 500 | -1.9% | 1.3% | 37.4% |
NIFTY PHARMA | -2.7% | -1.4% | 52% |
You may also like the below Video Courses
FAQ about SANOFI INDIA
Is SANOFI INDIA good for long term investment?
As on Apr 16,2024, the Fundamentals of SANOFI INDIA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SANOFI INDIA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SANOFI INDIA UnderValued or OverValued?
As on Apr 16,2024, SANOFI INDIA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SANOFI INDIA ?
As on Apr 16,2024, the Intrinsic Value of SANOFI INDIA is Rs. 6,188.17 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 6,462.52
Fair Value [Median EV / Sales Model] : Rs. 6,188.17
Fair Value [Median Price / Sales Model] : Rs. 6,015.65
Estimated Median Fair Value of SANOFI INDIA : Rs. 6,188.17
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.